Swaminathan Soumya, Luetkemeyer Annie, Srikantiah Padmini, Lin Royce, Charlebois Edwin, Havlir Diane V
Division of HIV/AIDS, Tuberculosis Research Centre, Chennai, India.
Trop Doct. 2006 Apr;36(2):73-9. doi: 10.1258/004947506776593387.
With the expansion and convergence of the HIV and TB epidemics worldwide, clinicians will increasingly will be called to manage and treat co-infected patients. TB and HIV medications have overlapping and additive toxicities that can complicate therapy. Additional clinical challenges include choice of optimal first and second line antiretroviral therapy, appropriate timing of antiretroviral initiation, management of immune reconstitution disease, and TB diagnosed after initiation of HIV therapy. Despite the complexities presented by co-infection, many programmes have integrated care and are successfully treating patients with both HIV and TB.
随着全球范围内艾滋病毒和结核病疫情的扩大与合并,临床医生将越来越多地被要求管理和治疗合并感染的患者。结核病和艾滋病毒药物具有重叠和累加的毒性,这可能使治疗变得复杂。其他临床挑战包括选择最佳的一线和二线抗逆转录病毒疗法、抗逆转录病毒治疗开始的合适时机、免疫重建疾病的管理以及在开始艾滋病毒治疗后诊断出的结核病。尽管合并感染带来了复杂性,但许多项目已经整合了护理,并成功地治疗了艾滋病毒和结核病患者。